Topic

Toggle navigation

speciality pharmaceuticals

This content is from: Research

Health Care – Pharmaceuticals/Speciality: 2012 Second

Gregory Gilbert of Bank of America Merrill Lynch takes second place for a fourth year in a row.

October 16, 2012
This content is from: Research

Health Care – Pharmaceuticals/Speciality: 2012 Third

Reclaiming third place, after two years in the runner-up position, is David Steinberg of Deutsche Bank Securities.

October 16, 2012
This content is from: Research

Health Care – Pharmaceuticals/Speciality: 2012 First

Aaron (Ronny) Gal Sanford C. Bernstein & Co. “He has the best access to management of all the analysts in his space.” Providing “very detailed work on the various international operations of the companies he covers,” as one portfolio manager puts it, helps Aaron (Ronny) Gal of Sanford C. Bernstein & Co

October 15, 2012
This content is from: Video

Pharmaceuticals Specialty: M&A Activity Will Continue to Drive Investor Interest

Evercore ISI's Umer Raffat, the sector's No. 1 analyst, is unabashedly bullish on speciality pharmaceuticals manufacturers, citing reasonable valuations and a high number of takeover targets.
By Editors
December 01, 2015
Sponsored

New Issue Performance Recap for the Week of 01/31/2006

February 01, 2006
Sponsored

New Issue Performance Recap for the Week of 2/28/06

March 01, 2006
See More Articles